简化免疫失调指数:一种预测脓毒症重症监护患者28天死亡率的新标志物
本研究在Peking Union Medical College Hospital开展,依据Sepsis 3.0标准纳入2018年5月至2022年10月的脓毒症患者,采用LASSO logistic回归筛选特征,比较IL-6/LY#比值与单独IL-6水平、淋巴细胞计数对28天死亡率的预测性能。研究队列死亡率为24.5%(220/898),IL-6/LY#在非存活者中显著高于存活者(348 [154.6-1371.7] vs. 42.3 [15.4-117.1]),其AUC为0.852(95% CI = 0.820-0.879),高于单独IL-6(0.776 [95% CI = 0.738-0.809])和LY#(0.719 [95% CI = 0.677-0.755])。生存分析显示IL-6/LY#对患者风险的预测显著优于SOFA评分或其他因素(P = 1.5 × 10^-33)。趋势分析中,D1-D3-D7 IL-6/LY#呈下降趋势者死亡率低于上升或波动组(高、中、低D1 IL-6/LY#组分别为42.1% vs. 58.3%、37.9% vs. 43.8%、37.5% vs. 38.5%)。
要点
- ICU首日IL-6/LY#比值在脓毒症非存活者中显著高于存活者(348 [154.6-1371.7] vs. 42.3 [15.4-117.1])。
- IL-6/LY#预测28天死亡的AUC为0.852(95% CI = 0.820-0.879),高于单独IL-6(0.776 [95% CI = 0.738-0.809])和LY#(0.719 [95% CI = 0.677-0.755])。
- 生存分析显示IL-6/LY#对死亡风险的预测显著优于SOFA评分或其他因素(P = 1.5 × 10^-33)。
- D1-D3-D7 IL-6/LY#呈下降趋势者死亡率低于上升或波动组(高D1组42.1% vs. 58.3%,中D1组37.9% vs. 43.8%,低D1组37.5% vs. 38.5%)。
- 研究队列28天死亡率为24.5%(220/898)。
适用人群与场景
- 依据Sepsis 3.0标准诊断的脓毒症患者,数据来自Peking Union Medical College Hospital 2018年5月至2022年10月的病历回顾。
诊断标准与关键阈值
- 脓毒症诊断依据Sepsis 3.0标准。
研究设计与关键结果
- 研究类型为在Peking Union Medical College Hospital开展的回顾性病历分析,纳入脓毒症患者898例,28天死亡率为24.5%(220/898)。
- 采用LASSO logistic回归筛选特征,识别出LY#、IL-6水平、血小板计数、SOFA评分、APACHE II评分、心率、年龄和FiO2水平为预测28天死亡率的关键因素,IL-6/LY#被确定为核心指标。
- 非存活者IL-6/LY#显著高于存活者(348 [154.6-1371.7] vs. 42.3 [15.4-117.1])。
- IL-6/LY#预测28天死亡的AUC为0.852(95% CI = 0.820-0.879),高于IL-6水平(0.776 [95% CI = 0.738-0.809])和LY#(0.719 [95% CI = 0.677-0.755])。
- Cox风险模型生存分析显示IL-6/LY#对死亡风险的预测显著优于SOFA评分或其他因素(P = 1.5 × 10^-33)。
- 趋势分析中,D1-D3-D7 IL-6/LY#下降趋势者死亡率低于上升或波动组:高D1 IL-6/LY#组42.1% vs. 58.3%,中D1组37.9% vs. 43.8%,低D1组37.5% vs. 38.5%。
证据类型、等级与局限
- 证据类型:回顾性病历分析(基于Peking Union Medical College Hospital 2018年5月至2022年10月数据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ICU首日检测的IL-6/LY#可作为免疫失衡预警指标,用于识别28天死亡风险较高的脓毒症患者。
- 作者认为,IL-6/LY#呈下降趋势提示脓毒症患者28天死亡率较低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. There is currently no simple immune-imbalance-driven indicator for patients with sepsis. Methods: This study was conducted in Peking Union Medical College Hospital. Patients with sepsis were identified according to Sepsis 3.0 after reviewing patient data from May 2018 through October 2022. Least absolute shrinkage and selection operator logistic regression was used for features selection. Receiver operating characteristic curves for 28-day mortality were used to compare the predictive performance of level of interleukin 6 (IL-6) and lymphocyte count (LY#) with that of the combined ratio, namely, the IL-6/LY# ratio. A Cox hazard model was also used to test the predictive performance of IL-6/LY# versus several other measurements. The dynamic trend of IL-6/LY# based on day 1 IL-6/LY# level was analyzed. Results: The mortality rate was 24.5% (220/898) in the study cohort. The LY#, IL-6 level, blood platelet count, Sequential Organ Failure Assessment score, Acute Physiology and Chronic Health Evaluation II score, heart rate, age and Fi o2 level were identified as key factors for predicting 28-day mortality. IL-6/LY# was identified as a core indicator according to Least absolute shrinkage and selection operator logistic regression analysis. IL-6/LY# was significantly higher in nonsurvivors than in survivors (348 [154.6-1371.7] vs. 42.3 [15.4-117.1]). IL-6/LY# yielded a higher area under the curve (0.852 [95% CI = 0.820-0.879]) than the level of IL-6 (0.776 [95% CI = 0.738-0.809]) and LY# (0.719 [95% CI = 0.677-0.755]) separately. Survival analysis of mortality risk versus the IL-6/LY# ratio suggested that IL-6/LY# was significantly more predictive of patient risk than the Sequential Organ Failure Assessment score or the other factors ( P = 1.5 × 10 -33 ). In trend analysis, as the trend of D1-D3-D7 IL-6/LY# decreases, the morality rate is lower than increase or fluctuate group (42.1% vs. 58.3%, 37.9% vs. 43.8%, 37.5% vs. 38.5% in high, moderate, and low D1 IL-6/LY# group separately). Conclusion: IL-6/LY# examined on first day in intensive care unit can be used as an immune-imbalance alert to identify sepsis patients with higher risk of 28-day mortality. Decreasing trend of IL-6/LY# suggests a lower 28-day mortality rate of sepsis patients.
参考来源
- Liu S, Zhuge C, Zhang J, et al. SIMPLIFIED IMMUNE-DYSREGULATION INDEX: A NOVEL MARKER PREDICTS 28-DAY MORTALITY OF INTENSIVE CARE PATIENTS WITH SEPSIS. Shock. 2024. PMID: 38411593. doi:10.1097/SHK.0000000000002316
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。